Nov 15 (Reuters) - Akcea Therapeutics Inc AKCA.O
* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS
* Akcea Therapeutics Inc - in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018
* Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS